Pilot evaluation of bupropion for the treatment of hot flashes

Domingo G. Pérez, Charles Lawrence Loprinzi, Jeff A Sloan, Paul Novotny, Debra Barton, Lisa Carpenter, Deanne Smith, Brad Christensen, Teresa Rummans

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Bupropion is commonly used in the treatment of nicotine dependence and depression, and in most people, does not cause sexual dysfunction, weight gain, or sedation. Given its attractive side effect profile, the efficacy of other newer antidepressants against hot flashes and anecdotal observations of resolution of hot flashes in some patients taking bupropion for nicotine dependence, it was decided to explore its clinical activity as a hot flash remedy in a pilot study. Between January 1999 and October 2004, 21 patients (7 men and 14 women) were enrolled in the study. Self-completed daily hot flash diaries were used to document the frequency and severity of hot flashes at baseline (week 1) and during the treatment period (weeks 2 through 5). Participants received bupropion 150 mg every morning for the first 3 days and then 150 mg twice per day for a total of 4 weeks. One woman did not provide any hot flash information and was excluded from the analysis. Five women could not complete the study because of side effects. The study did not show a reduction in hot flash frequency and/or severity significantly higher than what would be expected with a placebo. Even though the sample size was small, these results are consistent with bupropion's mechanism of action (norepinephrine reuptake inhibition without serotonergic effects) and what it is now hypothesized about the pathophysiology of hot flashes (increased noradrenergic activity and decreased serotonergic activity). These data suggest that bupropion should not be further investigated as a remedy for hot flashes.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalJournal of Palliative Medicine
Volume9
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Hot Flashes
Bupropion
Tobacco Use Disorder
Therapeutics
Sample Size
Antidepressive Agents
Weight Gain
Norepinephrine
Placebos
Depression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pilot evaluation of bupropion for the treatment of hot flashes. / Pérez, Domingo G.; Loprinzi, Charles Lawrence; Sloan, Jeff A; Novotny, Paul; Barton, Debra; Carpenter, Lisa; Smith, Deanne; Christensen, Brad; Rummans, Teresa.

In: Journal of Palliative Medicine, Vol. 9, No. 3, 06.2006, p. 631-637.

Research output: Contribution to journalArticle

Pérez, DG, Loprinzi, CL, Sloan, JA, Novotny, P, Barton, D, Carpenter, L, Smith, D, Christensen, B & Rummans, T 2006, 'Pilot evaluation of bupropion for the treatment of hot flashes', Journal of Palliative Medicine, vol. 9, no. 3, pp. 631-637. https://doi.org/10.1089/jpm.2006.9.631
Pérez, Domingo G. ; Loprinzi, Charles Lawrence ; Sloan, Jeff A ; Novotny, Paul ; Barton, Debra ; Carpenter, Lisa ; Smith, Deanne ; Christensen, Brad ; Rummans, Teresa. / Pilot evaluation of bupropion for the treatment of hot flashes. In: Journal of Palliative Medicine. 2006 ; Vol. 9, No. 3. pp. 631-637.
@article{37894e01362444dab8cb1d16d7230461,
title = "Pilot evaluation of bupropion for the treatment of hot flashes",
abstract = "Bupropion is commonly used in the treatment of nicotine dependence and depression, and in most people, does not cause sexual dysfunction, weight gain, or sedation. Given its attractive side effect profile, the efficacy of other newer antidepressants against hot flashes and anecdotal observations of resolution of hot flashes in some patients taking bupropion for nicotine dependence, it was decided to explore its clinical activity as a hot flash remedy in a pilot study. Between January 1999 and October 2004, 21 patients (7 men and 14 women) were enrolled in the study. Self-completed daily hot flash diaries were used to document the frequency and severity of hot flashes at baseline (week 1) and during the treatment period (weeks 2 through 5). Participants received bupropion 150 mg every morning for the first 3 days and then 150 mg twice per day for a total of 4 weeks. One woman did not provide any hot flash information and was excluded from the analysis. Five women could not complete the study because of side effects. The study did not show a reduction in hot flash frequency and/or severity significantly higher than what would be expected with a placebo. Even though the sample size was small, these results are consistent with bupropion's mechanism of action (norepinephrine reuptake inhibition without serotonergic effects) and what it is now hypothesized about the pathophysiology of hot flashes (increased noradrenergic activity and decreased serotonergic activity). These data suggest that bupropion should not be further investigated as a remedy for hot flashes.",
author = "P{\'e}rez, {Domingo G.} and Loprinzi, {Charles Lawrence} and Sloan, {Jeff A} and Paul Novotny and Debra Barton and Lisa Carpenter and Deanne Smith and Brad Christensen and Teresa Rummans",
year = "2006",
month = "6",
doi = "10.1089/jpm.2006.9.631",
language = "English (US)",
volume = "9",
pages = "631--637",
journal = "Journal of Palliative Medicine",
issn = "1096-6218",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Pilot evaluation of bupropion for the treatment of hot flashes

AU - Pérez, Domingo G.

AU - Loprinzi, Charles Lawrence

AU - Sloan, Jeff A

AU - Novotny, Paul

AU - Barton, Debra

AU - Carpenter, Lisa

AU - Smith, Deanne

AU - Christensen, Brad

AU - Rummans, Teresa

PY - 2006/6

Y1 - 2006/6

N2 - Bupropion is commonly used in the treatment of nicotine dependence and depression, and in most people, does not cause sexual dysfunction, weight gain, or sedation. Given its attractive side effect profile, the efficacy of other newer antidepressants against hot flashes and anecdotal observations of resolution of hot flashes in some patients taking bupropion for nicotine dependence, it was decided to explore its clinical activity as a hot flash remedy in a pilot study. Between January 1999 and October 2004, 21 patients (7 men and 14 women) were enrolled in the study. Self-completed daily hot flash diaries were used to document the frequency and severity of hot flashes at baseline (week 1) and during the treatment period (weeks 2 through 5). Participants received bupropion 150 mg every morning for the first 3 days and then 150 mg twice per day for a total of 4 weeks. One woman did not provide any hot flash information and was excluded from the analysis. Five women could not complete the study because of side effects. The study did not show a reduction in hot flash frequency and/or severity significantly higher than what would be expected with a placebo. Even though the sample size was small, these results are consistent with bupropion's mechanism of action (norepinephrine reuptake inhibition without serotonergic effects) and what it is now hypothesized about the pathophysiology of hot flashes (increased noradrenergic activity and decreased serotonergic activity). These data suggest that bupropion should not be further investigated as a remedy for hot flashes.

AB - Bupropion is commonly used in the treatment of nicotine dependence and depression, and in most people, does not cause sexual dysfunction, weight gain, or sedation. Given its attractive side effect profile, the efficacy of other newer antidepressants against hot flashes and anecdotal observations of resolution of hot flashes in some patients taking bupropion for nicotine dependence, it was decided to explore its clinical activity as a hot flash remedy in a pilot study. Between January 1999 and October 2004, 21 patients (7 men and 14 women) were enrolled in the study. Self-completed daily hot flash diaries were used to document the frequency and severity of hot flashes at baseline (week 1) and during the treatment period (weeks 2 through 5). Participants received bupropion 150 mg every morning for the first 3 days and then 150 mg twice per day for a total of 4 weeks. One woman did not provide any hot flash information and was excluded from the analysis. Five women could not complete the study because of side effects. The study did not show a reduction in hot flash frequency and/or severity significantly higher than what would be expected with a placebo. Even though the sample size was small, these results are consistent with bupropion's mechanism of action (norepinephrine reuptake inhibition without serotonergic effects) and what it is now hypothesized about the pathophysiology of hot flashes (increased noradrenergic activity and decreased serotonergic activity). These data suggest that bupropion should not be further investigated as a remedy for hot flashes.

UR - http://www.scopus.com/inward/record.url?scp=33745314443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745314443&partnerID=8YFLogxK

U2 - 10.1089/jpm.2006.9.631

DO - 10.1089/jpm.2006.9.631

M3 - Article

C2 - 16752968

AN - SCOPUS:33745314443

VL - 9

SP - 631

EP - 637

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

SN - 1096-6218

IS - 3

ER -